Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 4,450Xls
2D Structure
Also known as: Mb-07811, 852948-13-1, Mb07811, Vk-2809, Vk2809, Unii-3z11398fnq
Molecular Formula
C28H32ClO5P
Molecular Weight
515.0  g/mol
InChI Key
LGGPZDRLTDGYSQ-JADSYQMUSA-N
FDA UNII
3Z11398FNQ

VK-2809 is under investigation in clinical trial NCT02927184 (Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease).
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[[4-[[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,25-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol
2.1.2 InChI
InChI=1S/C28H32ClO5P/c1-18(2)25-14-21(8-9-27(25)30)15-26-19(3)12-24(13-20(26)4)32-17-35(31)33-11-10-28(34-35)22-6-5-7-23(29)16-22/h5-9,12-14,16,18,28,30H,10-11,15,17H2,1-4H3/t28-,35+/m0/s1
2.1.3 InChI Key
LGGPZDRLTDGYSQ-JADSYQMUSA-N
2.1.4 Canonical SMILES
CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OCP3(=O)OCCC(O3)C4=CC(=CC=C4)Cl
2.1.5 Isomeric SMILES
CC1=CC(=CC(=C1CC2=CC(=C(C=C2)O)C(C)C)C)OC[P@@]3(=O)OCC[C@H](O3)C4=CC(=CC=C4)Cl
2.2 Other Identifiers
2.2.1 UNII
3Z11398FNQ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

2. Mb 07811

3. Mb-07811

4. Mb07811

5. Vk2809

2.3.2 Depositor-Supplied Synonyms

1. Mb-07811

2. 852948-13-1

3. Mb07811

4. Vk-2809

5. Vk2809

6. Unii-3z11398fnq

7. Chembl457748

8. 3z11398fnq

9. Mb-07811 (vk-2809)

10. 4-[[4-[[(2r,4s)-4-(3-chlorophenyl)-2-oxo-1,3,2lambda5-dioxaphosphinan-2-yl]methoxy]-2,6-dimethylphenyl]methyl]-2-propan-2-ylphenol

11. (2r,4s)-4-(3-chlorophenyl)-2-((4-(4-hydroxy-3-isopropylbenzyl)-3,5-dimethylphenoxy)methyl)-1,3,2-dioxaphosphinane 2-oxide

12. Mb 07811

13. Schembl282796

14. Gtpl12768

15. Dtxsid501005783

16. Ex-a3394

17. Bdbm50401076

18. Akos040742104

19. Db15137

20. Compound 22c [pmid: 18975928]

21. Trans-(s)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxo-(1,3,2)dioxaphosphorinane

22. Hy-111288

23. Cs-0034844

24. Q27258223

25. (2r,4s)-4-(3-chlorophenyl)-2-((3,5-dimethyl-4-(4-hydroxy-3-isopropylbenzyl)phenoxy)methyl)-2-oxido-(1,3,2)-dioxaphosphonane

26. 2-((3,5-dimethyl-4-(4'-hydroxy-3'-isopropylbenzyl)phenoxy)methyl)-4-(3-chlorophenyl)-2-oxido(1,3,2)dioxaphosphonane

27. 4-(3-chlorophenyl)-2-[(4-{[4-hydroxy-3-(propan-2-yl)phenyl]methyl}-3,5-dimethylphenoxy)methyl]-1,3,2lambda~5~-dioxaphosphinan-2-one

2.4 Create Date
2007-02-21
3 Chemical and Physical Properties
Molecular Weight 515.0 g/mol
Molecular Formula C28H32ClO5P
XLogP36.9
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count5
Rotatable Bond Count7
Exact Mass g/mol
Monoisotopic Mass g/mol
Topological Polar Surface Area65
Heavy Atom Count35
Formal Charge0
Complexity708
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Investigated for use/treatment in hyperlipidemia.


5 Pharmacology and Biochemistry
5.1 Mechanism of Action

Studies indicate that targeting TR agonists to the liver has the potential to lower both LDL-cholesterol (the "bad" cholesterol) and both hepatic and plasma triglyceride levels.